Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection

被引:31
作者
Buijs, P. R. A. [1 ]
van Eijck, C. H. J. [1 ]
Hofland, L. J. [2 ]
Fouchier, R. A. M. [3 ]
van den Hoogen, B. G. [3 ]
机构
[1] Erasmus MC, Dept Surg, NL-3015 CE Rotterdam, Netherlands
[2] Erasmus MC, Dept Internal Med, Div Endocrinol, NL-3015 CE Rotterdam, Netherlands
[3] Erasmus MC, Dept Virosci, NL-3015 CE Rotterdam, Netherlands
关键词
pancreatic adenocarcinoma; oncolytic virotherapy; Newcastle disease virus; innate immunity; I INTERFERONS; CANCER-CELLS; TUMOR-CELLS; THERAPY; NDV; REPLICATION; TRIAL; CHEMOTHERAPY; GEMCITABINE; VIROTHERAPY;
D O I
10.1038/cgt.2013.78
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Newcastle disease virus (NDV) is a naturally occurring oncolytic virus with clinically proven efficacy against several human tumor types. Selective replication in and killing of tumor cells by NDV is thought to occur because of differences in innate immune responses between normal and tumor cells. In our effort to develop oncolytic virotherapy with NDV for patients with pancreatic cancer, we evaluated the responses to NDV infection and interferon (IFN) treatment of 11 different established human pancreatic adenocarcinoma cell lines (HPACs). Here we show that all HPACs were susceptible to NDV. However, this NDV infection resulted in different replication kinetics and cytotoxic effects. Better replication resulted in more cytotoxicity. No correlation was observed between defects in the IFN pathways and, NDV replication or NDV-induced cytotoxicity. IFN production by HPACS after NDV infection differed substantially. Pretreatment of HPACs with IFN resulted in diminished NDV replication and decreased the cytotoxic effects in most HPACs. These findings Suggest that not all HPACs have functional defects in the innate immune pathways, possibly resulting in resistance to oncolytic virus treatment. These data support the rationale for designing recombinant oncolytic NDVs with optimized virulence that should likely contain an antagonist of the IFN pathways.
引用
收藏
页码:24 / 30
页数:7
相关论文
共 45 条
[1]   Oncolytic Viruses: An Approved Product on the Horizon? [J].
Bell, John .
MOLECULAR THERAPY, 2010, 18 (02) :233-234
[2]   Cell-Type-Specific Innate Immune Response to Oncolytic Newcastle Disease Virus [J].
Biswas, Moanaro ;
Kumar, Sandeep R. P. ;
Allen, Adria ;
Yong, Wang ;
Nimmanapalli, Ramadevi ;
Samal, Siba K. ;
Elankumaran, Subbiah .
VIRAL IMMUNOLOGY, 2012, 25 (04) :268-276
[3]  
CASSEL WA, 1992, MED ONCOL TUMOR PHAR, V9, P169
[4]  
CASSEL WA, 1965, CANCER-AM CANCER SOC, V18, P863, DOI 10.1002/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO
[5]  
2-V
[6]   Oncolytic viruses [J].
Chiocca, EA .
NATURE REVIEWS CANCER, 2002, 2 (12) :938-950
[7]   Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy [J].
Elankumaran, Subbiah ;
Chavan, Vrushali ;
Qiao, Dan ;
Shobana, Raghunath ;
Moorkanat, Gopakumar ;
Biswas, Moanaro ;
Samal, Siba K. .
JOURNAL OF VIROLOGY, 2010, 84 (08) :3835-3844
[8]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
[9]   Tumor selective replication of Newcastle Disease Virus: Association with defects of tumor cells in antiviral defence [J].
Fiola, Christoph ;
Peeters, Ben ;
Fournier, Philippe ;
Arnold, Annette ;
Bucur, Mariana ;
Schirrmacher, Volker .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (02) :328-338
[10]   Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme [J].
Freeman, AI ;
Zakay-Rones, Z ;
Gomori, JM ;
Linetsky, E ;
Rasooly, L ;
Greenbaum, E ;
Rozenman-Yair, S ;
Panet, A ;
Libson, E ;
Irving, CS ;
Galun, E ;
Siegal, T .
MOLECULAR THERAPY, 2006, 13 (01) :221-228